420 related articles for article (PubMed ID: 31993875)
21. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
[TBL] [Abstract][Full Text] [Related]
22. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
23. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
Giralt M; Chocron S; Ferrer R; Ariceta G
Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
[TBL] [Abstract][Full Text] [Related]
24. X-linked hypophosphatemic rickets: an Italian experts' opinion survey.
Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP
Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
[TBL] [Abstract][Full Text] [Related]
26. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients.
Bosman A; Appelman-Dijkstra NM; Boot AM; de Borst MH; van de Ven AC; de Jongh RT; Bökenkamp A; van den Bergh JP; van der Eerden BCJ; Zillikens MC
Calcif Tissue Int; 2024 Mar; 114(3):255-266. PubMed ID: 38226986
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
28. Burosumab: Current status and future prospects.
Goyal A; Tandon N
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
[TBL] [Abstract][Full Text] [Related]
29. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Haffner D; Emma F; Eastwood DM; Duplan MB; Bacchetta J; Schnabel D; Wicart P; Bockenhauer D; Santos F; Levtchenko E; Harvengt P; Kirchhoff M; Di Rocco F; Chaussain C; Brandi ML; Savendahl L; Briot K; Kamenicky P; Rejnmark L; Linglart A
Nat Rev Nephrol; 2019 Jul; 15(7):435-455. PubMed ID: 31068690
[TBL] [Abstract][Full Text] [Related]
30. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study.
Lo SH; Lachmann R; Williams A; Piglowska N; Lloyd AJ
Qual Life Res; 2020 Jul; 29(7):1883-1893. PubMed ID: 32162120
[TBL] [Abstract][Full Text] [Related]
31. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
32. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
33. Hypophosphatemic Rickets with R179W Mutation in FGFR23 Gene - A Rare But Treatable Cause of Refractory Rickets.
Sandal S; Arora V; Verma IC
Indian J Pediatr; 2021 Jan; 88(1):61-63. PubMed ID: 32415663
[TBL] [Abstract][Full Text] [Related]
34. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
[TBL] [Abstract][Full Text] [Related]
37. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.
Trombetti A; Al-Daghri N; Brandi ML; Cannata-Andía JB; Cavalier E; Chandran M; Chaussain C; Cipullo L; Cooper C; Haffner D; Harvengt P; Harvey NC; Javaid MK; Jiwa F; Kanis JA; Laslop A; Laurent MR; Linglart A; Marques A; Mindler GT; Minisola S; Yerro MCP; Rosa MM; Seefried L; Vlaskovska M; Zanchetta MB; Rizzoli R
Nat Rev Endocrinol; 2022 Jun; 18(6):366-384. PubMed ID: 35484227
[TBL] [Abstract][Full Text] [Related]
38. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
[TBL] [Abstract][Full Text] [Related]
39. Rare PHEX intron variant causes complete and severe phenotype in a family with hypophosphatemic rickets: a case report.
Aiello F; Pasquali D; Baronio F; Cassio A; Rossi C; Di Fraia R; Carotenuto R; Digitale L; Festa A; Luongo C; Maltoni G; Schiano di Cola R; Del Giudice EM; Grandone A
J Pediatr Endocrinol Metab; 2023 Jan; 36(1):91-95. PubMed ID: 36351286
[TBL] [Abstract][Full Text] [Related]
40. [Rare causes of Hypophosphatemia: diagnostic approach].
Trombetti A; Fokstuen S; Parvex P
Rev Med Suisse; 2023 Apr; 19(823):770-775. PubMed ID: 37133959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
